Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Palatin Technologies (PTN – Research Report), retaining the price target ...

putting her in charge of the overall commercial strategy for Kailera’s pipeline of GLP-1 candidates to treat obesity and related conditions. Coleman most recently spent nearly two decades at Lilly.

Investor interest in companies with obesity candidates in their pipeline clearly remains high ... once-weekly oral treatment for obesity and weight loss maintenance that could dramatically ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

BioAge Labs is returning to its aging roots after a failed attempt in obesity R&D. To get the ball rolling again, the biotech has entered into a multi-year research collaboration worth up to $550 ...

BT: Are there other drugs in Eli Lilly’s pipeline targeting obesity or related conditions that we can expect in the near future? VG: India is an important market for Lilly. We are committed to ...